Italiano Farmacia on line: comprare cialis senza ricetta, acquistare viagra internet.

Microsoft word - samplereport1.5.docx

PATIENT INFORMATION
Patient Name
Patient ID
Diagnosis
Referring Physician
Exam Date
Accession Number
Primary Medication
Secondary Medication
As-Needed Medication
As-Needed Medication
NEUROTYPE GROUP
Efficacy Type
Resilience Type
Focus Type
Acceptance Type
RECOMMENDED PAIN CONTROL COGNITIVE STRATEGIES
NEUROTYPE GROUP BRAIN ANATOMICAL CHARACERISTICS
Left Brain / Side View
Left Brain / Mid View
Right Brain / Side View
Right Brain /Mid View
NEUROTYPE GROUP BRAIN FUNCTIONAL CHARACERISTICS
Axial Coronal
Sagittal
Values are presented for informational purposes only. This report is not a medical diagnosis and should not be used to guide medical treatment. For that purpose please see your physician.  
PATIENT INFORMATION
Patient Name
Patient ID
Diagnosis
Referring Physician
Exam Date
Accession Number
Primary Medication
Secondary
As-Needed Medication
As-Needed Medication
Medication
CURRENT PAIN DIAGNOSIS VS. NEUROTYPE GROUP
Pain Severity vs. Group Based on Diagnosis:
Pain Severity vs. Group Based on Age:
Patient is at 45th percentile within group. Patient is at 20th percentile within group. Patient (red *) in Group (blue distribution)
Patient (red *) in Group (blue distribution)
Values are presented for informational purposes only. This report is not a medical diagnosis and should not be used to guide medical treatment. For that purpose please see your physician.  
PATIENT INFORMATION
Patient Name
Patient ID
Diagnosis
Referring Physician
Exam Date
Accession Number
Primary Medication
Secondary
As-Needed Medication
As-Needed Medication
Medication
FUTURE PAIN PROGNOSIS VS. NEUROTYPE GROUP
Pain Severity vs. Group Based on Diagnosis:
Pain Severity vs. Group Based on Age:
Patient is at 85th percentile within group.
Values are presented for informational purposes only. This report is not a medical diagnosis and should not be used to guide medical treatment. For that purpose please see your physician.  
PATIENT INFORMATION
Patient Name
Patient ID
Diagnosis
Referring Physician
Exam Date
Accession Number
Primary Medication
Secondary
As-Needed Medication
As-Needed Medication
Medication
OVERALL SUMMARY AND CONCLUSIONS
Patient NeuroType
Patient is in: Internal, Fluidity, Realist, Identifying NeuroType group.
This group accounts for 4.34% of the total population, 6.27% of the population of pain patients.
Patients within this group demonstrate adaptive behavior when dealing with pain flare-ups and are rarely
dependent on opioid medication. These patients are able to achieve relief through a combination of their
confidence in treatment options, understanding how these options can work for them, and focus on how
to achieve their treatment goals. These patients identify with their pain condition which can lead to
catastrophizing behavior in some cases.
Pain Strategy Recommendations
An internal-efficacy patient should focus on state inhibition (for negative affective states) and planning to
define a specific model for their treatment pathway. Fluid-resilient patients should focus on visualization,
and lapse detection to maintain focus when executing their plans. Realist-focus patients should focus on
attention / distraction techniques and context manipulation. Identifying-acceptance patients should
emphasize component identification to break complex problems into manageable blocks, and reappraisal
to manipulate the importance of these components.
Patient Current Pain (Diagnostic)
Patient is currently at 45th percentile within NeuroType group, meaning that:
 45% of patients within this group have lower pain severity  55% of patients within this group have higher pain severity. Patient is currently at 20th percentile within Age group, meaning that:  20% of patients within this group have lower pain severity  80% of patients within this group have higher pain severity.
Estimated Patient Future Pain (Prognostic)
Patient is estimated to be at 85th percentile of NeuroType group in the future, meaning that:
 Patient is estimated to show improvement greater than 85% of patients within the group.
 Patient is estimated to show improvement below 15% of patients within the group. Patient is predicted to experience "significant" pain relief of at least 50%, an amount associated with a "good" prognosis. These patients can typically achieve pain relief by maintaining their existing treatment pathway. Pain strategy recommendations for these patients emphasize understanding this pathway, appreciating their role within this pathway, and learning mechanisms to maximize focus throughout. These patients often benefit from instruction regarding cognitive drivers of pain flare-ups and attentional strategies that can minimize their impact. Values are presented for informational purposes only. This report is not a medical diagnosis and should not be used to guide medical treatment. For that purpose please see your physician.

Source: http://www.brainpatternresearch.com/px1/001/SampleReport1.5.pdf

Casefarmaceutiche_brevetti_e bioinvestimenti.pub

Newsletter Case farmaceutiche, tra brevetti in sca- In questo numero denza ed investimenti nelle biotecnologie - I farmaci tradizionali stanno per subire una seria minaccia dai ri- spettivi generici Aprile 2010 – A breve le case farmaceutiche tradizionali dovranno fare i conti con la sca- denza di molti brevetti riguardanti farmaci importanti. Per sopperire

Microsoft word - nppaprice.doc

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary, dated the 19th May, 2006) National Pharmaceutical Pricing Authority S.O. 758(E) In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of

Copyright © 2010-2014 Drugstore Pdf Search